Relationship between Plasminogen Activator Inhibitor-1 (PAI-1) and Beta Fibrinogen Polymorphisms with Unexplained Recurrent Pregnancy Loss
/ 1
- Details
- Category: Vol. 84, December 2016
- Hits: 600
Relationship between Plasminogen Activator Inhibitor-1 (PAI-1) and Beta Fibrinogen Polymorphisms with Unexplained Recurrent Pregnancy Loss, YEHIA A. WAFA, TAMER F. OOF, RABEI A. HASSANEIN and MOHAMED I. FARAHAT
Abstract
Background : Recurrent Pregnancy Loss (RPL), is dis-tressing for the patient and the cause is unknown in half of the cases and risk of it incrases with the number of previous pregnancy losses.
Objective: The objective of this study was to identify the associations of the Plasminogen Activator Inhibitor-1 (PAI-1) and beta fibrinogen polymorphisms with Recurrent Preg-nancy Loss (RPL).
Subjects and Methods: A cross-sectional, case-control study including 185 patients who had recurrent pregnancy loss as a patients group and 125 women who did not have any history of pregnancy loss as a control group. This study carried out at El-Hussein University Hospital in the period from November 2011 until October 2013.
Results: There was significant increase in PAI-1 4G/5G polymorphism in cases of recurrent pregnancy loss. Where there's significant difference in p value, OR ratio of the PAI-1 for 4G/5G polymorphism between patients and controls where p-value and odds ratio of genotype 4G/5G was (0.019, 0.586) respectively and for 4G/4G were (0.023, 1.679) respec-tively, while, the p-value, OR ratio of 5G/5G genotype were (0.041, 1.449) respectively. Also, there's significant difference in frequency, p-value and OR ratio of the 4G alleless PAI-1 4G/5G polymorphism between patients and controls where the number and percentages of 4G alleles among patients and controls were 162 (43.78%) in the patients and 111 (44.4%) in controls respectively and for 5G allele were 208 (56.22%) in patient, 139 (55.6%) in controls. The p-value and OR ratio of both 4G and 5G alleles were the same (0.05, 0.975).
Also, there's significant difference in p-value, OR ratio of the genotype [3-fibrinogen 455 G/A polymorphism between patients and controls. Where p-value and of genotype G/G were (0.005, 0.519) respectively and for A/A were (0.049, 1.623) respectively, while, the p-value, OR ratio of hetero-zygous G/A genotype were (0.024, 1.798) respectively. Also, there's significant difference in frequency, p-value and OR ratio of the alleless [3-fibrinogen 455 G/A polymorphism between patients and controls where the number and precent